A Former IVF Baby on "Three-Parent IVF"
By Jessica Cussins,
The Huffington Post
| 10. 24. 2013
I have my parents, and biotechnology, to thank for bringing me into this world; I was an IVF baby. Given this intimate connection with technology and test tubes, you might think I'd be a cheerleader for all developments in the field. But a new technique under consideration has broad and troubling implications, not only for hopeful parents-to-be and their potential future children, but for all of humanity.
This new technique, called mitochondrial replacement or "three-parent IVF," would make genetic changes to IVF embryos and thus to every cell of the children born as a result of it. And these changes would be passed down to future generations. Human inheritable genetic modification of this kind is currently prohibited in over 40 countries and by several international agreements due to numerous problems and concerns. But proposals that would break this long-respected international consensus are now under consideration in the United Kingdom and the United States.
The UK has been toying with the idea for some time and may soon change its law to allow clinical trials. Several US researchers also want...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...